Current Trends in Biomarkers for Traumatic Brain Injury

Area of Science:

• Neurotrauma research
• Biomarker discovery

Background:

• Traumatic Brain Injury (TBI) is a significant health concern with no current precision or regenerative therapies.
• Effective biomarkers for rapid TBI diagnosis and prognosis are critically needed to mitigate severity and adverse effects.

Purpose of the Study:

• To review the utility of various potential biomarkers for the diagnosis and prognosis of TBI.
• To identify reliable biomarkers for robust TBI assessment.

Main Methods:

• Literature review of established and emerging biomarkers for TBI.
• Analysis of biomarkers in blood, CSF, saliva, and urine.
• Evaluation of S100B, GFAP, NSE, MBP, UCHL1, tau protein, and alpha spectrin II breakdown products.

Main Results:

• Current blood biomarkers like cytokines and chemokines offer limited utility.
• Specific biomarkers including S100B, GFAP, NSE, MBP, UCHL1, tau protein, and alpha spectrin II breakdown products show promise.
• In vivo imaging modalities provide some diagnostic value.

Conclusions:

• A combination of biomarkers is likely necessary for robust TBI diagnosis and prognosis.
• Further validation of these biomarkers is essential for clinical application in TBI management.